

2. Finsterer J, Scorza FA. Guillain-Barre syndrome in 220 patients with COVID-19. *Egypt J Neurol Psychiatr Neurosurg.* 2021;57:55, <http://dx.doi.org/10.1186/s41983-021-00310-7>.
3. Gigli GL, Vogrig A, Nilo A, Fabris M, Biasotto A, Curcio F, et al. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome. *Neurol Sci.* 2020;41:3391–4, <http://dx.doi.org/10.1007/s10072-020-04787-7>.

J. Finsterer\*, F.A. Scorza

*Disciplina de Neurociência, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo, Brazil*

\* Corresponding author.

E-mail address: [fifigs1@yahoo.de](mailto:fifigs1@yahoo.de) (J. Finsterer).

<https://doi.org/10.1016/j.medin.2021.12.007>

0210-5691/ © 2022 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

## Reply to ‘‘Ample evidence suggests SARS-CoV-2 triggers polyradiculitis’’



### Respuesta a «Una amplia evidencia sugiere que el SARS-CoV-2 desencadena la polirradiculitis»

Dear Editor:

Firstly, we would like to thank Finsterer and their partners for reading our article<sup>1</sup> with so much interest and dedication. As well as the *Medicina Intensiva* Journal for their kindness allowing us to make the reply that we will develop next.

In June 2020, we published in the online version of this journal, an article<sup>2</sup> showing the clinical case of a 55 year old patient with SARS-CoV-2 infection and neurological symptoms, in which after performing the relevant tests, a sensory-motor polyneuropathy was detected. Being this article, the first Guillain-Barré syndrome (GBS) case reported in Spain, in the course of an infection by the SARS-CoV-2 virus and in addition, supporting the hipótesis spread from China, in January 2020, GBS associated with SARS-CoV-2, chance or coincidence?<sup>3</sup>

Subsequently, such was our concern that we conducted a bibliographic search in the Medline database (PubMed) on published cases of GBS in the worldwide context of SARS-CoV-2 infection. Starting from December 2019 to June 30, 2020, with a total of 39 clinical cases reported. Immediately after the data collection and statistical analysis, we sent a letter to the editor of the *Medicina Intensiva* Journal; available online since September 2020 and titled: SARS-CoV-2, a new causative agent of Guillain-Barré syndrome?<sup>1</sup> Finsterer et al., show their disagreement due to the lack of conviction in our publication about the association of GBS and SARS-CoV-2, and even allude to the fact that vac-

nation can also trigger GBS. From our utmost respect, we would like to emphasize the time difference, more than a year between both publications. Therefore, the experience and the increase in the number of subsequent cases have shown the strength of the SARS-CoV-2 and GBS association. On the whole, the authors, when writing these publications, only suspected this binomial. Furthermore, the process of immunization by the vaccines had not even started.

## References

1. Esteban Molina A, Mata Martínez M, Sánchez Chueca P, Carrillo López A. SARS-CoV-2, A new causative agent of Guillain-Barré syndrome? *Med Intensiva.* 2020, <http://dx.doi.org/10.1016/j.medin.2020.08.009>. S0210-5691(20)30274-6.
2. Esteban Molina A, Mata Martínez M, Sánchez Chueca P, Carrillo López A, Sancho Val I, Sanjuan-Villarreal TA. Guillain-Barré syndrome associated with SARS-CoV-2 infection. *Med Intensiva.* 2020, <http://dx.doi.org/10.1016/j.medin.2020.04.015>. S0210-5691(20)30154-6.
3. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *Lancet Neurol.* 2020;19:383–4, [http://dx.doi.org/10.1016/S1474-4422\(20\)30109-5](http://dx.doi.org/10.1016/S1474-4422(20)30109-5).

A. Esteban Molina\*, M. Mata Martínez, P. Sánchez Chueca

*Servicio de Medicina Intensiva, Hospital Universitario Miguel Servet, Zaragoza, Spain*

\* Corresponding author.

E-mail address: [a.estebanmolina@hotmail.com](mailto:a.estebanmolina@hotmail.com)

(A. Esteban Molina).

<https://doi.org/10.1016/j.medin.2022.01.014>

0210-5691/ © 2022 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.